Antimalarial activity of the triple combination of proguanil, atovaquone and dapsone

Acta Tropica

Volumn 67, Issue 3, 1997, Pages 207-214

  Yeo, A E T ^a   Edstein, M D ^a   Rieckmann, K H ^a  

^a NONE

Author keywords

Atovaquone; Cycloguanil; Dapsone; Malaria; Plasmodium falciparum; Proguanil

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; DAPSONE; PROGUANIL; NAPHTHOQUINONE;

AGRANULOCYTOSIS; ANTIMALARIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENTIATION; HUMAN; MALARIA; MINIMUM INHIBITORY CONCENTRATION; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME; ANIMAL; DRUG COMBINATION; DRUG EFFECT; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; THAILAND;

ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHLOROGUANIDE; DAPSONE; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; NAPHTHOQUINONES; PLASMODIUM FALCIPARUM; THAILAND;

EID: 0031591834     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(97)00060-0     Document Type: Article

References (31)

1. Black, R.H., 1973. Malaria in the Australian Army in South Vietnam. Successful use of a proguanil-dapsone combination for chemoprophylaxis of chloroquine-resistant falciparum malaria. Med. J. Aust. 1, 1265-1270.
2. Black, R.H., Ray, A.P., 1977. Experimental studies of the potentiation of proguanil and pyrimethamine by dapsone using Plasmodium berghei in white mice. Ann. Trop. Med. Parasitol. 71, 131-139.
3. Bygbjerg, I., Ravn, P., Ronn, A., Flachs, H., Hvidberg, E.F., 1987. Human pharmacokinetics of proguanil and its metabolites. Trop. Med. Parasit. 38, 77-80.
4. Canfield, C.J., Pudney, M., Gutteridge, W.E., 1995. Interactions of Atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp. Parasitol. 80, 373-381.
5. Desjardins, R.E., Doberstyn, E.B., Wernsdorfer, W.H., 1988. The treatment and prophylaxis of malaria. In: Wernsdorfer, W.H., McGregor, I. (Eds.), Malaria: Principles and Practice of Malariology, Vol. I. Churchill Livingstone, Edinburgh, London, Melbourne and New York.
6. Edstein, M.D., Shanks, G.D., Teja-Isavadharm, P., Rieckmann, K.H., Webster, H.K., 1994. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br. J. Clin. Pharmacol. 37, 67-70.
7. Edstein, M.D., Yeo, A.E.T., Kyle, D.E., Looareesuwan, S., Wilairatana, P., Rieckmann, K.H., 1996. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. Trans. Roy. Soc. Trop. Med. Hyg. 90, 418-421.
8. Ferone, R., Burchall, J.J., Hitchings, G.H., 1969. Plasmodium berghei dihydrofolate reductase. Isolation, properties and inhibition by antifolates. Mol. Pharmacol. 5, 49-59.
9. Fisk, T.L., Millet, P., Collins, W.E., Nguyen-Dinh, P., 1988. In vitro activity of antimalarial compounds on the exoerythrocytic stages of Plasmodium cynomolgi and P. knowlesi. Am. J. Trop. Med. Hyg. 40, 235-239.
10. Fry, M., Pudney, M., 1992. Site of action of antimalarial hydroxynaphthoquinone, 2-(trans-4-(4′-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol. 43, 1545-1553.
11. GlaxoWellcome, The role of Malarone in antimalarial chemotherapy. XIVth International Congress for Tropical Medicine and Malaria, Nagasaki, Japan.
12. Haile, L.G., Flaherty, J.F., 1993. Atovaquone: A review.. Ann. Pharmacother. 27, 1488-1494.
13. Helsby, N.A., Ward, S.A., Edwards, G., Howells, R.E., Breckenridge, A.M., 1990. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br. J. Clin. Pharmacol. 30, 593-598.
14. Hitchings, G.H., Burchall, J.J., 1965. Inhibition of folate biosynthesis and function as a basis for chemotherapy. Adv. Enzymol. 27, 417-468.
15. Howells, R.E., Gilles, H.M., Bent, N.S., 1985. A comparison of the pyrimethamine and cycloguanil sensitivities of the pre-erythrocytic and erythrocytic stages of drug-sensitive and drug-resistant strains of Plasmodium yoelii. Ann. Trop. Med. Parasitol. 79, 247-251.
16. Hudson, A.T., Dickins, M., Ginger, C.D., Gutteridge, W.E., Holdich, T., Hutchinson, D.B.A., Pudney, M., Randall, A.W., Latter, V.S., 1991. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp. Clin. Res. XVII, 427-435.
17. Hughes, W., Leoung, G., Kramer, F., Bozzette, S.A., Safrin, S., Frame, P., Clumeck, N., Masur, H., Lancaster, D., Chan, C., Lavelle, J., Rosenstock, J., Falloon, J., Feinberg, J., LaFon, S., Rogers, M., Sattler, F., 1993. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. Lancet 328, 1521-1527.
18. Karwacki, J.J., Shanks, G.D., Limsomwong, N., Singharaj, P., 1990. Proguanil-sulphonamide for malaria prophylaxis. Trans. R. Soc. Trop. Med. Hyg. 84, 55-57.
19. Kovacs, J.A., 1992. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet 340, 637-638.
20. Lambros, C., Vanderberg, J.P., 1979. Synchronisation of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65, 418-420.
21. Looareesuwan, S., Viravan, C., Webster, H.K., Kyle, D.E., Hutchinson, D.B., Canfield, C.J., 1996. Clinical studies of atovaquone alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54, 62-66.
22. McCulloch, J.L., Maren, T.H., 1974. Dihydropteroate synthetase from Plasmodium berghei: isolation, properties and inhibition by dapsone and sulfadiazine. Mol. Pharmacol. 10, 140-145.
23. Shanks, G.D., Edstein, M.D., Chedester, L.A., Smith, C.D., Corcoran, K.D., Ngampochjana, M., Hansukjariya, P., Sattabongkot, J., Webster, H.K., 1994. Proguanil plus sulfamethoxazole is not causally prophylactic in the macaca mulatta-Plasmodium cynomolgi model. Am. J. Trop. Med. Hyg. 50, 641-645.
24. Rolan, P.E., Mercer, A.J., Weatherley, B.C., Holdich, T., Meire, H., Peck, R.W., Ridout, G., Posner, J., 1994. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br. J. Clin. Pharmacol. 37, 13-20.
25. Smithurst, B.A., Robertson, I., Naughton, M.A., 1971. Dapsone induced agranulocytosis complicated by Gram negative septicaemia. Med. J. Aust. 1, 537-539.
26. Thaithong, S., Beale, G.H., 1981. Resistance of ten Thai isolates of Plasmodium falciparum to chloroquine and pyrimethamine by in vitro tests. Trans. Roy. Soc. Trop. Med. Hyg. 75, 271-273.
27. Trager, W., Jensen, J.B., 1976. Human malaria parasites in continuous culture. Science 193, 673-675.
28. Watkins, W.M., Brandling-Bennett, A.D., Nevill, C.G., Carter, J.Y., Boriga, D.A., Howells, R.E., Koech, D.K., 1988. Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Trans. Roy. Soc. Trop. Med. Hyg. 82, 398-403.
29. Watkins, W.M., Mberu, E.K., Nevill, C.G., Ward, S.A., Breckenridge, A.M., Koech, D.K., 1990. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans. Roy. Soc. Trop. Med. Hyg. 84, 492-495.
30. Wattanagoon, Y., Taylor, R.B., Moody, R.R., Ochekpe, N.A., Looareesuwan, S., White, N.J., 1987. Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br. J. Clin. Pharmacol. 24, 775-780.
31. Yeo, A.E.T., Seymour, K.K., Rieckmann, K.H. and Christopherson, R.I., 1997. Effects of dual combinations of antifolates and atovaquone or dapsone on nucleotide levels in Plasmodium falciparum. Biochem. Pharmacol. (in press).